Cancer Archives

News and Trends 24 Aug 2017

Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer

Merck Ventures has joined the team of investors behind Macrophage Pharma, a biotech in Windsor, UK, using macrophages against cancer. Macrophage Pharma is a young biotech working on a new approach to boost the immune system’s ability to attack tumor cells. Its technology attracted £9M (€9.8M) in Series A earlier this year from the CRT Pioneer […]

August 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Aug 2017

First-in-Human Trial will test a New Cancer Therapy from Switzerland

Cellestia Biotech will start human trials with CB-103, an anticancer drug targeting the Notch signaling pathway, known for its ubiquity in cancer. Cellestia Biotech, based in Basel, has announced it received full approval to start clinical trials in Spain with CB-103, a new class of drug that targets an ubiquitous cancer mechanism. The drug is a […]

August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immatics cancer personalized cell therapy

News and Trends 21 Aug 2017

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced today the start of its first clinical trial testing its cell therapy technology aimed at providing personalized treatments for multiple types of solid tumors. The […]

August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Aug 2017

Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes

A team of Swedish researchers has published today an interactive map for the visualization of the effects of individual cancer genes that supports personalized medicine. The new Pathology Atlas is an open access online resource containing genomic data from over 8,000 patients across 17 major cancer types. By typing in the name of any gene […]

August 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Mundipharma CellAct Biliary Tract Cancer

News and Trends 14 Aug 2017

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Mundipharma has acquired the rights to CAP7.1, a drug that could bring the first alternative to surgery and chemo for patients with biliary tract cancer. Cambridge-based Mundipharma has paid $250M (€212M) to the German biotech CellAct in exchange for the worldwide development, commercialization and manufacturing rights to CAP7.1. The candidate is a prodrug that, when metabolized, […]

August 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotecnol cancer research uk immuno oncology

News and Trends 11 Aug 2017

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase […]

August 11, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 2 Aug 2017

Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy

TC Biopharm has just received the largest award of its kind to develop allogeneic gamma-delta T cell therapies for various cancers. Based in Glasgow, TC Biopharm was just selected to receive €4M from Horizon 2020 for its “off-the-shelf” gamma-delta T cell program. This grant brings the company’s fundraising total to €25M, and it’s the largest any UK […]

August 2, 2017 - 3 minutesmins - By Evelyn Warner

Cancer immunotherapy resistance mechanism University Hospital Zurich

News and Trends 27 Jul 2017

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca imfinzi durvalumab tremelimumab

News and Trends 27 Jul 2017

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

SHIVA Trial Precision Medicine Cancer France

In Depth 20 Jul 2017

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […]

July 20, 2017 - 5 minutesmins - By Timothé Cynober

Tiziana Life Sciences HCC milciclib cancer

News and Trends 19 Jul 2017

Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer

Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […]

July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer

First-in-Human Trial will test a New Cancer Therapy from Switzerland

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

Roche Abandons Spanish Cancer Epigenetics Drug

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!